Eculizumab for atypical hemolytic uremic syndrome in pregnancy

Gianluigi Ardissino, Manuela Wally Ossola, Giulia Maria Baffero, Angelo Rigotti, Massimo Cugno

Research output: Contribution to journalArticlepeer-review


Background: Atypical hemolytic uremic syndrome (HUS) is a thrombotic microangiopathy often caused by mutations in complement genes. During pregnancy, disease outcome is poor both for mother and fetus. Since 2009, the humanized monoclonal antibody eculizumab has been successfully used in the treatment of atypical HUS in nonpregnant patients. Case: A 26-year-old woman with a homozygous mutation in complement factor H developed a relapse of atypical HUS at 17 weeks of gestation in her first pregnancy. Because the disease remained active despite multiple plasma exchanges, eculizumab was started at 26 weeks of gestation. It was well tolerated and has led to remission and to the delivery of a healthy neonate. Conclusion: Eculizumab may be useful for the treatment of atypical HUS during pregnancy.

Original languageEnglish
Pages (from-to)487-489
Number of pages3
JournalObstetrics and Gynecology
Issue number2 PART2
Publication statusPublished - Aug 2013

ASJC Scopus subject areas

  • Obstetrics and Gynaecology


Dive into the research topics of 'Eculizumab for atypical hemolytic uremic syndrome in pregnancy'. Together they form a unique fingerprint.

Cite this